CL2017003436A1 - Compuestos de benzoxacepina oxazolidinona y métodos de uso - Google Patents

Compuestos de benzoxacepina oxazolidinona y métodos de uso

Info

Publication number
CL2017003436A1
CL2017003436A1 CL2017003436A CL2017003436A CL2017003436A1 CL 2017003436 A1 CL2017003436 A1 CL 2017003436A1 CL 2017003436 A CL2017003436 A CL 2017003436A CL 2017003436 A CL2017003436 A CL 2017003436A CL 2017003436 A1 CL2017003436 A1 CL 2017003436A1
Authority
CL
Chile
Prior art keywords
methods
pi3k
benzoxacepin
oxazolidinone compounds
compounds
Prior art date
Application number
CL2017003436A
Other languages
English (en)
Inventor
Marie-Gabrielle Braun
Richard Elliott
Emily Hanan
Robert Andrew Heald
Calum Macleod
Steven T Staben
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017003436A1 publication Critical patent/CL2017003436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>EN EL PRESENTE DOCUMENTO SE DESCRIBEN COMPUESTOS DE BENZOXACEOINA OXAZOLIDINONA CON ACTIVIDAD O FUNCIÓN MODULADORA DE FOSFOINOSITIDO 3 CINASA (PI3K) QUE TIENEN LA ESTRUCTURA DE FÓRMULA 1, O ESTEREOISÓMEROS, TAUTÓMEROS, O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, Y CON LOS SUSTITUYENTES Y CARACTERÍSTICAS ESTRUCTURALES DESCRITAS EN EL PRESENTE DOCUMENTO. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS Y MEDICAMENTOS QUE INCLUYEN LOS COMPUESTOS DE FÓRMULA 1, ASÍ COMO MÉTODOS PARA USAR DICHOS MODULADORES DE PI3K, SOLOS O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA TRATAR ENFERMEDADES O AFECCIONES QUE ESTÁN MEDIADAS O QUE SON DEPENDIENTES DE LA DESREGULACIÓN DE PI3K.</p>
CL2017003436A 2015-07-02 2017-12-28 Compuestos de benzoxacepina oxazolidinona y métodos de uso CL2017003436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562188029P 2015-07-02 2015-07-02

Publications (1)

Publication Number Publication Date
CL2017003436A1 true CL2017003436A1 (es) 2018-05-04

Family

ID=56292756

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003436A CL2017003436A1 (es) 2015-07-02 2017-12-28 Compuestos de benzoxacepina oxazolidinona y métodos de uso

Country Status (36)

Country Link
US (8) US9650393B2 (es)
EP (6) EP3317284B1 (es)
JP (4) JP6523490B2 (es)
KR (2) KR102306071B1 (es)
CN (4) CN112062778B (es)
AR (1) AR105238A1 (es)
AU (2) AU2016287463B2 (es)
CA (1) CA2982708C (es)
CL (1) CL2017003436A1 (es)
CO (1) CO2017011038A2 (es)
CR (1) CR20170563A (es)
DK (1) DK3317284T3 (es)
ES (2) ES2908300T3 (es)
FI (1) FIC20253008I1 (es)
FR (1) FR25C1039I1 (es)
HR (1) HRP20192349T1 (es)
HU (2) HUE046756T2 (es)
IL (3) IL255200B (es)
LT (2) LT3317284T (es)
MA (3) MA42295B1 (es)
MX (2) MX388533B (es)
MY (1) MY195002A (es)
NL (1) NL301344I2 (es)
NO (1) NO2025044I1 (es)
PE (2) PE20211775A1 (es)
PH (2) PH12017502425A1 (es)
PL (2) PL3317284T3 (es)
PT (1) PT3317284T (es)
RS (1) RS59740B1 (es)
RU (1) RU2730529C2 (es)
SG (1) SG10201913980SA (es)
SI (1) SI3317284T1 (es)
TW (4) TWI649326B (es)
UA (1) UA121678C2 (es)
WO (1) WO2017001645A1 (es)
ZA (2) ZA201808370B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
TWI649326B (zh) 2015-07-02 2019-02-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其製備方法
TWI788830B (zh) 2015-07-02 2023-01-01 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
JP6873977B2 (ja) 2015-09-08 2021-05-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 三環式ｐｉ３ｋ阻害化合物及び使用方法
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
ES2953833T3 (es) * 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP6998969B2 (ja) 2017-04-28 2022-02-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト （ｓ）－２－（（２－（（ｓ）－４－（ジフルオロメチル）－２－オキソオキサゾリジン－３－イル）－５，６－ジヒドロベンゾ［ｆ］イミダゾ［１，２－ｄ］［１，４］オキサゼピン－９－イル）アミノ）プロパンアミドの多形体及び固体形態と、生産方法
JP7398391B2 (ja) 2018-04-20 2023-12-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
WO2019228341A1 (zh) * 2018-05-30 2019-12-05 江苏豪森药业集团有限公司 含三并环类衍生物抑制剂、其制备方法和应用
TW202430189A (zh) * 2018-07-23 2024-08-01 瑞士商赫孚孟拉羅股份公司 用pi3k抑制劑gdc-0077治療癌症之方法
TW202027736A (zh) 2018-10-08 2020-08-01 瑞士商赫孚孟拉羅股份公司 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
CN109265408B (zh) * 2018-12-11 2020-09-01 上海皓元生物医药科技有限公司 二氟甲基取代噁烷-2-酮的合成方法
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN111995541B (zh) * 2019-05-27 2025-05-06 君实润佳(上海)医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
ES3061133T3 (en) 2019-08-26 2026-03-31 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN114599656A (zh) * 2019-11-04 2022-06-07 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
KR20220119610A (ko) * 2019-11-25 2022-08-30 상하이 한서 바이오메디컬 컴퍼니 리미티드 3개의 융합된 고리 유도체-함유 염 또는 결정 형태 및 이의 약학 조성물
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
TW202602448A (zh) * 2019-12-03 2026-01-16 美商建南德克公司 用於乳癌治療之組合療法
CA3204489A1 (en) * 2020-12-11 2022-06-16 Genentech, Inc. Combination therapies for treatment of her2 cancer
CN121085940A (zh) * 2021-01-29 2025-12-09 广州嘉越医药科技有限公司 三并环类化合物及其应用
TWI808648B (zh) 2021-02-16 2023-07-11 美商建南德克公司 使用包含gdc-9545及gdc-0077之組合療法治療乳癌
AU2022275275A1 (en) 2021-05-13 2023-12-14 Betta Pharmaceuticals Co., Ltd Polymorph of imidazolidinone compound, preparation method therefor and use thereof
BR112023024764A2 (pt) * 2021-05-28 2024-02-15 Genentech Inc Compostos, processos para preparar um composto de fórmula (8c), para preparar um composto de fórmula (8a) e para preparar um composto de fórmula (9-1) e processo para fazer um composto de fórmula (10-2)
JP7537026B2 (ja) 2021-07-19 2024-08-20 京セラ株式会社 通信方法、ユーザ装置、ネットワーク装置、移動通信システム、プログラム及びチップセット
CN118159534A (zh) * 2021-08-09 2024-06-07 蝎子疗法股份有限公司 抑制PI3K同工型α的化合物和用于治疗癌症的方法
CN119013026A (zh) 2022-04-06 2024-11-22 基因泰克公司 用于治疗癌症的包含gdc-6036和gdc-0077的组合疗法
WO2024022435A1 (zh) * 2022-07-27 2024-02-01 南京明德新药研发有限公司 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2024206147A1 (en) 2023-03-24 2024-10-03 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
IL326408A (en) 2023-08-11 2026-04-01 Hoffmann La Roche Pharmaceutical formulation comprising a coated tablet
TW202532065A (zh) 2023-12-04 2025-08-16 美商建南德克公司 治療乳癌之組合療法
WO2025122745A1 (en) 2023-12-05 2025-06-12 Genentech, Inc. Combination therapies for treatment of her2 cancer
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
DK2223922T3 (en) * 2000-04-25 2016-06-06 Icos Corp Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CA2550735A1 (en) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
MX2007013780A (es) 2005-05-04 2008-02-05 Pfizer Ltd Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
RU2439074C2 (ru) 2006-04-26 2012-01-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
GB0610866D0 (en) 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
JP5524853B2 (ja) * 2007-11-21 2014-06-18 デコード ジェネティクス イーエイチエフ 肺疾患及び心臓血管疾患を治療するための置換されたベンゾアゾールｐｄｅ４阻害剤
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CA2772691C (en) * 2009-09-28 2017-10-03 F. Hoffmann-La Roche Ag Benzoxazepin pi3k inhibitor compounds and methods of use
AU2010299820A1 (en) * 2009-09-28 2012-04-19 F. Hoffmann-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
WO2011056930A2 (en) * 2009-11-06 2011-05-12 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
BR112013024122A2 (pt) 2011-03-21 2019-09-24 Hoffmann La Roche compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
NO3175985T3 (es) 2011-07-01 2018-04-28
PE20141381A1 (es) 2011-07-01 2014-10-21 Novartis Ag Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
EA025407B1 (ru) 2012-03-05 2016-12-30 Джилид Калистога Ллс Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
KR20140141700A (ko) * 2012-03-30 2014-12-10 브라이엄 영 유니버시티 마찰 교반 작업의 처리 제어를 위한 작용력 조정
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
EP3404032B1 (en) * 2013-03-13 2025-07-02 F. Hoffmann-La Roche AG Process for making benzoxazepin compounds
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
TWI649326B (zh) 2015-07-02 2019-02-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其製備方法
ES2953833T3 (es) 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
JP6998969B2 (ja) * 2017-04-28 2022-02-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト （ｓ）－２－（（２－（（ｓ）－４－（ジフルオロメチル）－２－オキソオキサゾリジン－３－イル）－５，６－ジヒドロベンゾ［ｆ］イミダゾ［１，２－ｄ］［１，４］オキサゼピン－９－イル）アミノ）プロパンアミドの多形体及び固体形態と、生産方法
TW202430189A (zh) 2018-07-23 2024-08-01 瑞士商赫孚孟拉羅股份公司 用pi3k抑制劑gdc-0077治療癌症之方法
TW202027736A (zh) 2018-10-08 2020-08-01 瑞士商赫孚孟拉羅股份公司 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
TW202602448A (zh) 2019-12-03 2026-01-16 美商建南德克公司 用於乳癌治療之組合療法

Also Published As

Publication number Publication date
JP2019178135A (ja) 2019-10-17
CN111909173B (zh) 2025-03-04
TW201712020A (zh) 2017-04-01
MX2017016344A (es) 2018-05-02
JP7266630B2 (ja) 2023-04-28
JP2023103242A (ja) 2023-07-26
AU2020204418B2 (en) 2022-02-03
EP4696380A2 (en) 2026-02-18
EP4212536B1 (en) 2025-02-19
IL272277A (en) 2020-02-27
KR102306071B1 (ko) 2021-10-01
IL272277B (en) 2021-01-31
PE20211775A1 (es) 2021-09-08
US11760753B2 (en) 2023-09-19
KR20190100432A (ko) 2019-08-28
US20240199594A1 (en) 2024-06-20
MX2020003415A (es) 2021-12-07
PL3567045T3 (pl) 2022-04-19
ZA201808370B (en) 2023-03-29
EP3778607A1 (en) 2021-02-17
US20250326745A1 (en) 2025-10-23
KR102014326B1 (ko) 2019-08-26
IL255200B (en) 2020-05-31
HUS2500040I1 (hu) 2025-10-28
FR25C1039I1 (fr) 2025-11-21
MY195002A (en) 2022-12-30
JP2018519307A (ja) 2018-07-19
US9650393B2 (en) 2017-05-16
HRP20192349T1 (hr) 2020-03-20
ES2908300T3 (es) 2022-04-28
ZA202500997B (en) 2025-10-29
RS59740B1 (sr) 2020-02-28
WO2017001645A1 (en) 2017-01-05
NZ736222A (en) 2024-05-31
LTPA2025536I1 (es) 2025-10-10
CA2982708C (en) 2023-10-03
NL301344I2 (nl) 2025-11-10
CN112062778A (zh) 2020-12-11
TW202108592A (zh) 2021-03-01
CN112062778B (zh) 2024-04-19
CN112047960B (zh) 2024-08-02
IL277774A (en) 2020-11-30
AU2020204418A1 (en) 2020-07-23
US10112932B2 (en) 2018-10-30
CA2982708A1 (en) 2017-01-05
CO2017011038A2 (es) 2018-02-09
US20180127404A1 (en) 2018-05-10
US20250197386A1 (en) 2025-06-19
AU2016287463A1 (en) 2017-10-26
MX388533B (es) 2025-03-20
RU2018103454A3 (es) 2019-11-21
TWI601732B (zh) 2017-10-11
EP3778607B1 (en) 2023-08-30
EP3778607C0 (en) 2023-08-30
ES2764497T3 (es) 2020-06-03
EP3317284A1 (en) 2018-05-09
EP3317284B1 (en) 2019-10-30
EP4585597A1 (en) 2025-07-16
JP6523490B2 (ja) 2019-06-05
KR20180006460A (ko) 2018-01-17
HUE046756T2 (hu) 2020-03-30
PL3317284T3 (pl) 2020-04-30
SI3317284T1 (sl) 2020-02-28
RU2018103454A (ru) 2019-08-05
UA121678C2 (uk) 2020-07-10
MA49861A (fr) 2021-05-05
RU2730529C2 (ru) 2020-08-24
HK1253003A1 (zh) 2019-06-06
CN111909173A (zh) 2020-11-10
MX372624B (es) 2020-05-07
AU2016287463B2 (en) 2020-07-02
EP4696380A3 (en) 2026-04-29
US20170210733A1 (en) 2017-07-27
AR105238A1 (es) 2017-09-20
NZ775526A (en) 2024-05-31
JP2021119144A (ja) 2021-08-12
TWI698440B (zh) 2020-07-11
TWI649326B (zh) 2019-02-01
US20210246129A1 (en) 2021-08-12
CN107873032B (zh) 2020-07-17
IL255200A0 (en) 2017-12-31
MA54252A (fr) 2022-04-27
EP4212536A1 (en) 2023-07-19
NO2025044I1 (no) 2025-09-23
US20190263793A1 (en) 2019-08-29
JP6880101B2 (ja) 2021-06-02
PH12017502425A1 (en) 2018-07-02
PE20181021A1 (es) 2018-06-27
MA42295B1 (fr) 2020-02-28
PH12020551315A1 (en) 2021-07-05
BR112017023121A2 (pt) 2018-07-10
FIC20253008I1 (fi) 2025-09-22
DK3317284T3 (da) 2020-01-13
US10851091B2 (en) 2020-12-01
SG10201913980SA (en) 2020-03-30
LT3317284T (lt) 2020-01-27
CN112047960A (zh) 2020-12-08
EP3567045A1 (en) 2019-11-13
CN107873032A (zh) 2018-04-03
EP3567045B1 (en) 2022-01-12
TW201815798A (zh) 2018-05-01
EP4212536C0 (en) 2025-02-19
PT3317284T (pt) 2020-01-10
US20170015678A1 (en) 2017-01-19
CR20170563A (es) 2018-02-20
TW201936612A (zh) 2019-09-16

Similar Documents

Publication Publication Date Title
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2021009673A (es) Moduladores de ror-gamma.
CL2019001993A1 (es) Inhibidores selectivos de jak1.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
UY37098A (es) Moduladores de ror-gamma
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2019002810A1 (es) Compuestos inhibidores de ask1 y usos de los mismos.
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112018006259A2 (pt) &#34;adjunto compressível com estruturas de suporte intermediárias&#34;
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
MX2017014375A (es) Moduladores del ccr2.
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.